Kanser erken teşhis ve tarama eğitim merkezleri'ne KETEM başvuran kadınlarda Human Papillomavirüs HPV sıklığının değerlendirilmesi ve genotiplerin analizi

Year 2019, Volume: 76 Issue: 2, 163 - 168, 01.06.2019

Özgur Kan Umit Gorkem Ahmet Barış Özgur Kocak Cihan Togrul Engin Yıldırım

Abstract

Amaç: Serviks kanseri Türkiye’de en sık görülen jinekolojik kanserler arasındadır. Human papillomavirüs HPV genotipleri ile servikal maligniteler arasında kuvvetli bir neden sonuç ilişkisi mevcuttur ve bölgeler arasında bu genotiplerin dağılımı farklılıklar göstermektedir. HPV dağılımı üzerine yapılmış populasyon temelli epidemiyolojik çalışmaların eksikliği sebebiyle prevalans ile ilgili veriler kısıtlıdır. Çalışmanın amacı, Çorum ilindeki human papillomavirüs HPV pozitiflik oranlarının ve yüksek riskli HPV tiplerinin dağılımlarının incelenerek Türkiye genelinde HPV haritası çıkarılmasıdır.Yöntem: Çorum ili Kanser Erken Teşhis ve Tarama Eğitim Merkezleri KETEM ’ne, Ağustos 2014 ile Ocak 2018 yılları arasında başvuran toplam 33.649 kadın dahil edilmiştir. Çalışma öncesi üniversite etik kurulundan gerekli onamlar alınmıştır. Servikal sürüntü örnekleri HPV-DNA inceleme için toplanmış ve polimeraz zincir reaksiyonu PCR yöntemi ile HPV DNA araştırılmıştır. HPV DNA sonucunun pozitif olduğu belirlenen olgularda genotiplendirme için yeniden analiz yapılmıştır. Ek olarak, HPV pozitif olan olgularda sitolojik inceleme sonuçları karşılaştırılmıştır.of the patients. HPV DNA was positive in 1108 cases, The highest risk subtypes for cervical cancer, Type 16 and 18, were 14.69% and 1.17%, respectively. When cytological results of HPV DNA positive women were examined; 66.52% of the patients had no precancerous lesion and infection-related cytology results were observed in 41.34% of these patients. The most frequent cytologic abnormal result was LGSIL with Conclusion: HPV typing studies are increasingly important in cervical cancer screening. Considering the regional differences and the heterogeneity of the studies, the results of the Ministry of Health’s screening program in 2019 will guide the assessment of the prevalence. By mapping HPV genotypes and evaluating advanced data across all country, appropriate vaccination and prevention policies can be developed.Sonuç: HPV tiplendirme serviks kanseri tarama programlarında giderek önem kazanmaktadır. Bölgesel farklılıklar ve literatürde yer alan çalışmaların metodolojisindeki heterojen dağılım düşünüldüğünde; Sağlık beklenen Türkiye geneli tarama programı sonuçları HPV prevalansının ve bölgeler arasındaki dağılımın değerlendirilmesinde yol gösterici olacaktır. HPV genotiplerinin yaygınlığının değerlendirilmesi ve ülkenin her bölgesinden edinilen verilerin analizi ile uygun aşılama ve korunma politikaları geliştirilebilir.Bakanlığı’nın yılında yayımlaması

Keywords

Human papillomavirüs, serviks kanseri, genotip, Türkiye

Evaluation of the frequency of Human Papillomavirus HPV in women admitted to cancer early diagnosis and screening training centers KETEM and analysis of HPV genotypes

Abstract

Objective: CCervical cancer is one of the most common gynecologic cancers among women in Turkey. Human papillomavirus genotypes HPV are strongly associated with cervical malignancies, and the distribution of HPV genotypes varies regionally. Data on prevalence are limited due to the lack of population based epidemiological studies on HPV distribution. The purpose of the study was to assess HPV positivity rates, detect high- risk HPV types in Corum and obtain HPV mapping of Turkey.Methods: A total of 33.649 patients who applied to Cancer Early Diagnosis, Screening and Training Centers KETEM between August 2014 and January 2018 were included in this study. Prior to the study, permission was obtained from the ethics committee of the university. Cervical swab samples were collected for HPV-DNA examination and polymeraze chain reaction PCR method used to detect HPV DNA. Genotyping was performed in HPV DNA positive samples. In addition, cytologic examination results were also recorded in patients with HPV positives.Results: HPV DNA positivity was found in 3.29% Serviks kanseri kadınlarda en sık görülen dördüncü kanser olup tüm dünyada kanser ilişkili kadın ölümlerinin önemli bir kısmını oluşturmaktadır 1 . Dünya genelinde, büyük kısmı aşı ile önlenebilecek, yılda yaklaşık yarım milyon serviks kanseri olgusunun tanı aldığı düşünülmektedir 2 . Ülkemizde ise Sağlık Bakanlığı Kanser Dairesi verilerine göre yılda 1695 kadın serviks kanseri tanısı almaktadır ve kadınlarda görülen en sık 10. kanser konumundadır 3 . Serviks kanserlerinin tamamına yakınında sebep yüksek riskli human papilloma virüs HPV pozitifliği ve persistan HPV enfeksiyonudur 4 . HPV, 200’den of the patients. HPV DNA was positive in 1108 cases, The highest risk subtypes for cervical cancer, Type 16 and 18, were 14.69% and 1.17%, respectively. When cytological results of HPV DNA positive women were examined; 66.52% of the patients had no precancerous lesion and infection-related cytology results were observed in 41.34% of these patients. The most frequent cytologic abnormal result was LGSIL with Conclusion: HPV typing studies are increasingly important in cervical cancer screening. Considering the regional differences and the heterogeneity of the studies, the results of the Ministry of Health’s screening program in 2019 will guide the assessment of the prevalence. By mapping HPV genotypes and evaluating advanced data across all country, appropriate vaccination and prevention policies can be developed

Keywords

Human papilomavirus, cervical cancer, genotype, Turkey

References

• 1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer, 2015; 136(5): 359-86.
• 2. World Health Organization. Bulletin of the World Health Organization (BLT). 2006; 84 (2): 84-9.
• 3. Kanser Daire Başkanlığı. Türkiye Kanser İstatistikleri. Ankara, 2015.
• 4. Ronco G, Dillner J, Elfström KM, Tunesi S, Snijders PN, Arbyn M, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: followup of four European randomized controlled trials. Lancet, 2014; 383(9916): 524-32.
• 5. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, et al. Epidemiologic classification of human papillomavirustypes associated with cervical cancer. N Engl J Med, 2003; 348: 518-27.
• 6. de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol, 2010; 11(11): 1048-56.
• 7. Peirson L, Fitzpatrick-Lewis D, Ciliska D, Warren R. Screening for cervical cancer: a systematic review and meta-analysis. Syst Rev, 2013; 2: 35.
• 8. Whitlock EP, Vesco KK, Eder M, Lin JS, Senger CA, Burda BU. Liquid-based cytology and human papillomavirus testing to screen for cervical cancer: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med, 2011; 155(10): 687-97.
• 9. Feldman S. Human papillomavirus testing for primary cervical cancer screening; is it time to abandon Papanicolaou testing? JAMA Intern Med, 2014; 174: 1539-40.
• 10. Koliopoulos G, Arbyn M, Martin-Hirsch P, Kyrgiou M, Prendiville W, Paraskevaidis E. Diagnostic accuracy of human papillomavirus testing in primary cervical screening: A systematic review and meta-analysis of non-randomized studies. Gynecol Oncol, 2007; 104: 232-46.
• 11. CliffordGM, Rana RK, Franceschi S, Smith JS, Gough G, Pimenta JM. Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev, 2005; 14(5): 1157-64.
• 12. International Agency for Research on Cancer (IARC). 2007a. Summary of data reported and evaluations: IARC monographs on the evaluation of carcinogenic risks to humans. Volume 90. Human papillomaviruses. Lyon: World Health Organization. pp 465–477.
• 13. Guckan R, Kilinc C, Gozdemir E, Gurcaglar AA, Nergiz O. Prevalence and distribution of high-risk human papillomavirus in Amasya region, Turkey. Biomed Res, 2016; 27(3): 769-72.
• 14. Altun Z, Yarkın F, Vardar MA, Uğuz AH. The prevalence of human papilloma virus infection among women who admitted to Cukurova university faculty of medicine hospital. J Med Sci, 2011; 31: 307-14.
• 15. Akcali S, Goker A, Ecemis T, Kandiloglu AR, Sanlidag T. Human papilloma virus frequency and genotype distrubution in a Turkish population. Asian Pac J Cancer Prev, 2013; 14(1): 503-6.
• 16. Dursun P, Senger SS, Arslan H, Kuscu E, Ayhan A. Human papillomavirus (HPV) prevalence and types among Turkish women at a gynecology outpatient unit. BMC Infect Dis, 2009; 9: 191.
• 17. Köse F, Turan T. Tumorogenesis of cervical cancer and HPV. Turkiye Klinikleri J Gynecol Obst-Special Topics, 2009; 2(1): 13-8.
• 18. Clifford GM, Gallus S, Herrero R, Munoz N, Snijders PJ, Vaccarella S, et al. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet, 2005; 366(9490): 991-8.
• 19. Chen X, Xu H, Xu W, Zeng W, Liu J, Wu Q, et al. Prevalence and genotype distribution of human papillomavirus in 961,029 screening tests in southeastern China (Zhejiang Province) between 2011 and 2015. Sci Rep, 2017; 7(1): 14813.